DIA Stock Analysis: DiaSorin S.p.A. | MI
Diagnostics & Research | MI, Italy | Market Cap: 3.788m EUR | 12M Return: 8.2% | IT0003492391 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.0M
Qual. Beats: 0
Rev. Trend: 79.8%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DiaSorin S.p.A. is an Italian diagnostics company founded in 1968 and headquartered in Saluggia, Italy. It researches, manufactures, and distributes immunodiagnostic and molecular diagnostic test kits across Europe, North America, and other international markets. Its portfolio spans infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology, with flagship automated analyzer platforms sold under the LIAISON XL and LIAISON XS brand names.
The company also sells molecular diagnostic kits such as the Simplexa congenital CMV direct kit, the LIAISON PLEX Respiratory Flex Assay, and the LIAISON PLEX Yeast Blood Culture Assay, and incorporates the xMAP multiplex technology platform within its in vitro diagnostics offering. Its customers are primarily hospital and reference clinical laboratories, and a large share of revenue is generated from the recurring sale of proprietary reagents and consumables that run on DiaSorin-installed instruments, a typical commercial model in the in vitro diagnostics industry. The business sits within the global in vitro diagnostics (IVD) market, where regulatory clearances (e.g., FDA, CE-IVD) and an installed base of automated immunoassay analyzers are central to competitive positioning.
- LIAISON XL and XS reagent sales drive recurring diagnostic revenue
- Luminex acquisition expands molecular diagnostics margins and assay portfolio
- IVDR EU regulation increases compliance costs and product certification timelines
| Net Income: 211.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 2.92 > 1.0 |
| NWC/Revenue: 19.01% < 20% (prev 16.80%; Δ 2.21% < -1%) |
| CFO/TA 0.17 > 3% & CFO 480.0m > Net Income 211.3m |
| Net Debt (908.1m) to EBITDA (404.2m): 2.25 < 3 |
| Current Ratio: 1.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.9m) vs 12m ago 3.72% < -2% |
| Gross Margin: 64.48% > 18% (prev 65.66%; Δ -1.17% > 0.5%) |
| Asset Turnover: 60.54% > 50% (prev 42.37%; Δ 18.18% > 0%) |
| Interest Coverage Ratio: 11.27 > 6 (EBIT TTM 275.9m / Interest Expense TTM 24.5m) |
| A: 0.11 (Total Current Assets 752.2m - Total Current Liabilities 420.6m) / Total Assets 2.90b |
| B: 0.58 (Retained Earnings 1.69b / Total Assets 2.90b) |
| C: 0.10 (EBIT TTM 275.9m / Avg Total Assets 2.88b) |
| D: 0.96 (Book Value of Equity 1.42b / Total Liabilities 1.48b) |
| Altman-Z'' = 4.31 = AA |
| DSRI: 0.74 (Receivables 236.4m/222.2m, Revenue 1.74b/1.22b) |
| GMI: 1.02 (GM 65.66% / 64.48%) |
| AQI: 1.00 (AQ_t 0.65 / AQ_t-1 0.65) |
| SGI: 1.44 (Revenue 1.74b / 1.22b) |
| TATA: -0.09 (NI 211.3m - CFO 480.0m) / TA 2.90b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at EUR 78.80 with a total of 104,002 shares traded. Over the past week, the price has changed by +2.85%, over one month by +3.74%, over three months by +18.67% and over the past year by +8.22%.
Current recommended Stop Loss: 74.60 (which is 5.3% or 2.4 ATR below the current price).
DiaSorin S.p.A. has no consensus analysts rating.
P/E Trailing = 28.1691
P/E Forward = 21.5983
P/S = 3.2175
P/B = 2.6613
P/EG = 1.6228
Revenue TTM = 1.74b EUR
EBIT TTM = 275.9m EUR
EBITDA TTM = 404.2m EUR
Long Term Debt = 730.7m EUR (from longTermDebt, last quarter)
Short Term Debt = 170.3m EUR (from shortTermDebt, last quarter)
Debt = 1.03b EUR (from shortLongTermDebtTotal, last quarter) + Leases 69.5m
Net Debt = 908.1m EUR (calculated: Debt 1.03b - CCE 120.9m)
Enterprise Value = 4.70b EUR (3.79b + Debt 1.03b - CCE 120.9m)
Interest Coverage Ratio = 11.27 (Ebit TTM 275.9m / Interest Expense TTM 24.5m)
EV/FCF = 11.43x (Enterprise Value 4.70b / FCF TTM 410.9m)
FCF Yield = 8.75% (FCF TTM 410.9m / Enterprise Value 4.70b)
FCF Margin = 23.55% (FCF TTM 410.9m / Revenue TTM 1.74b)
Net Margin = 12.11% (Net Income TTM 211.3m / Revenue TTM 1.74b)
Gross Margin = 64.48% ((Revenue TTM 1.74b - Cost of Revenue TTM 619.6m) / Revenue TTM)
Gross Margin QoQ = 64.78% (prev 65.16%)
Tobins Q-Ratio = 1.62 (Enterprise Value 4.70b / Total Assets 2.90b)
Interest Expense / Debt = 2.38% (Interest Expense 24.5m / Debt 1.03b)
Taxrate = 28.03% (82.3m / 293.6m)
NOPAT = 198.6m (EBIT 275.9m * (1 - 28.03%))
Current Ratio = 1.79 (Total Current Assets 752.2m / Total Current Liabilities 420.6m)
Debt / Equity = 0.72 (Debt 1.03b / totalStockholderEquity, last quarter 1.42b)
Debt / EBITDA = 2.25 (Net Debt 908.1m / EBITDA 404.2m)
Debt / FCF = 2.21 (Net Debt 908.1m / FCF TTM 410.9m)
Total Stockholder Equity = 1.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.33% (Net Income 211.3m / Total Assets 2.90b)
RoE = 13.91% (Net Income TTM 211.3m / Total Stockholder Equity 1.52b)
RoCE = 12.27% (EBIT 275.9m / Capital Employed (Equity 1.52b + L.T.Debt 730.7m))
RoIC = 7.76% (NOPAT 198.6m / Invested Capital 2.56b)
WACC = 5.74% (E(3.79b)/V(4.82b) * Re(6.83%) + D(1.03b)/V(4.82b) * Rd(2.38%) * (1-Tc(0.28)))
Discount Rate = 6.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 46.04 | Cagr: 2.12%
[DCF] Terminal Value 77.97% ; FCFF base≈375.9m ; Y1≈430.9m ; Y5≈634.1m
[DCF] Fair Price = 174.6 (EV 9.54b - Net Debt 908.1m = Equity 8.63b / Shares 49.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.21 | # QB: 0
Revenue Correlation: 79.84 | Revenue CAGR: 12.33% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.91 | Chg30d=-1.04% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=3.86 | Chg30d=-0.29% | Revisions=+0% | GrowthEPS=-8.8% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=4.28 | Chg30d=-0.99% | Revisions=+22% | GrowthEPS=+10.7% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: +15% (up=6, down=4)